Dr. Christopher P. Parrish, MD
Pediatrics (Pediatric Allergy/Immunology Physician)
At a glance
- In the NPI registry since
- 2009
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Allergy/Immunology Physician primary
TX license Q8992 (first issued 2016; delinquent - incomplete registration) -
Allergy & Immunology Physician
CA license A106557 (first issued 2025; current) -
Internal Medicine Physician
CA license A106557 (first issued 2025; current) -
Pediatrics Physician
CA license A106557 (first issued 2025; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $137 in total to this clinician.
| Genzyme Corporation | $57.89 |
|---|---|
| Genentech USA, Inc. | $22.23 |
| Ars Pharmaceuticals Operations, Inc. | $21.83 |
| Integra Lifesciences Corporation | $19.67 |
| Galderma Laboratories, L.P. | $15.43 |
| Food and Beverage | $137 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $27,172 in research payments for these studies, mostly to the institutions running them.
- Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals, Inc. · Completed · NCT04394351
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.